Lomitapide is a microsomal triglyceride transfer protein inhibitor for patients with homozygous familial hypercholesterolaemia. Due to its mechanism of action, potential hepatic effects of lomitapide are of clinical interest. This study aimed to determine the long-term hepatic safety of lomitapide.
Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia / L. Dominique, D. Laura, O. Sallyann, A. Marcello, I. Working Group on Lomitapide: Angelo Baldassare Cefalù, A. Di Costanzo, S. Bini, A. Giammanco, M. Averna, G. Iannuzzo, G. Fortunato, M. Gentile, M. Donata Di Taranto, A. Pujia, T. Montalcini, C. Pavanello, L. Calabresi, G. Battista Vigna, M. Bucci, K. Bonomo, T. Sampietro, F. Sbrana, P. Suppressa, C. Sabbà, F. Fimiani, A. Cesaro, P. Calabrò, F. Ventura, S. D'Addato, L. Pisciotta, S. Bertolini. - In: LIVER INTERNATIONAL. - ISSN 1478-3223. - 43:2(2023 Feb), pp. 413-423. [10.1111/liv.15497]
Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
C. Pavanello;L. Calabresi;
2023
Abstract
Lomitapide is a microsomal triglyceride transfer protein inhibitor for patients with homozygous familial hypercholesterolaemia. Due to its mechanism of action, potential hepatic effects of lomitapide are of clinical interest. This study aimed to determine the long-term hepatic safety of lomitapide.
| File | Dimensione | Formato | |
|---|---|---|---|
|
bmjebm-2022-111944.full.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
2.01 MB
Formato
Adobe PDF
|
2.01 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
